Evidence map›Paper›PMID 33923087›Full record

SynthesisInternational journal of molecular sciences2021

A Systematic Review and Meta-Analysis of Pharmacogenetic Studies in Patients with Chronic Kidney Disease.

Maria Tziastoudi, Georgios Pissas, Georgios Raptis, Christos Cholevas, Theodoros Eleftheriadis, Evangelia Dounousi, Ioannis Stefanidis, Theoharis C Theoharides

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Role of Mast Cells and Their Mediators in Chronic Kidney Diseases.International journal of molecular sciences · 2025
    Review
  5. Review
  6. Article
  7. Impact of theFrontiers in cardiovascular medicine · 2024
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Maria TziastoudiDepartment of Nephrology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece.ORCID 0000-0002-7206-2716
Georgios PissasDepartment of Nephrology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece.
Georgios RaptisProtypo Bioiatriko Laboratory, 41110 Larissa, Greece.
Christos CholevasAHEPA Hospital, First Department of Ophthalmology, Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, 54621 Thessaloniki, Greece.
Theodoros EleftheriadisDepartment of Nephrology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece.ORCID 0000-0001-9302-1633
Evangelia DounousiDepartment of Nephrology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0002-1172-1829
Ioannis StefanidisDepartment of Nephrology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece.
Theoharis C TheoharidesDepartment of Immunology, Tufts University School of Medicine, Boston, MA 02155, USA.
University of Thessaly · GRAristotle University of Thessaloniki · GRTufts University · USUniversity of Ioannina · GR

Funding

EU-Fund for Peripheral Growth, Action "Epeiros 2014-2020" supporting health and biotechnology of the Epeiros Region, Greece, in the frame of the program "e-health drug interaction control platform and person-alized medication in patients with CKD" ΗΠ1ΑΒ-00039
6 · The paper itself

Abstract

Chronic kidney disease (CKD) is an important global public health problem due to its high prevalence and morbidity. Although the treatment of nephrology patients has changed considerably, ineffectiveness and side effects of medications represent a major issue. In an effort to elucidate the contribution of genetic variants located in several genes in the response to treatment of patients with CKD, we performed a systematic review and meta-analysis of all available pharmacogenetics studies. The association between genotype distribution and response to medication was examined using the dominant, recessive, and additive inheritance models. Subgroup analysis based on ethnicity was also performed. In total, 29 studies were included in the meta-analysis, which examined the association of 11 genes (16 polymorphisms) with the response to treatment regarding CKD. Among the 29 studies, 18 studies included patients with renal transplantation, 8 involved patients with nephrotic syndrome, and 3 studies included patients with lupus nephritis. The present meta-analysis provides strong evidence for the contribution of variants harbored in the

Indexed as

Pharmacogenomic TestingPharmacogenomic VariantsAzathioprineCyclosporineHumansPolymorphism, GeneticPrednisoloneRenal Insufficiency, ChronicTacrolimusTreatment OutcomeAzathioprineCyclosporinePrednisoloneTacrolimuschronic kidney diseasegenetic associationmeta-analysispharmacogeneticssystematic review

Identifiers

PMID33923087
PMCPMC8123337
OpenAlexW3158494081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.